1.
Summary of characteristics for patients treated with afatinib in LUX-Lung 3 and 6
| Characteristics | Count/median (%/IQR) |
| Age group (years) | |
| 27-65 | 314 (67.1%) |
| 65-86 | 154 (32.9%) |
| Gender | |
| Female | 299 (63.9%) |
| Male | 169 (36.1%) |
| Race | |
| Asian | 404 (86.3%) |
| White | 61 (13%) |
| Other | 3 (0.6%) |
| Smoking history | |
| Never smoked | 332 (70.9%) |
| Ex or current smoker | 136 (29.1%) |
| Time since diagnosis | |
| < 12 months | 421 (90%) |
| > 12 months | 47 (10%) |
| ECOG PS | |
| 0 | 140 (29.9%) |
| 1+ | 328 (70.1%) |
| EGFR mutation type | |
| DEL19 | 235 (50.3%) |
| L858R | 180 (38.5%) |
| Other | 41 (8.8%) |
| T790M | 11 (2.4%) |
| WT | 1 (0.2%) |
| Stage at screening | |
| IIIB | 34 (7.3%) |
| IV | 434 (92.7%) |
| Continued | |